Evidence map›Paper›PMID 29156764›Full record

ArticleOncotarget2017

The NEIL1 G83D germline DNA glycosylase variant induces genomic instability and cellular transformation.

Heather A Galick, Carolyn G Marsden, Scott Kathe, Julie A Dragon, Lindsay Volk, Antonia A Nemec, Susan S Wallace, Aishwarya Prakash, Sylvie Doublié, Joann B Sweasy

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. The Link Between Human Alkyladenine DNA Glycosylase and Cancer Development.International journal of molecular sciences · 2025
    Review
  3. Aflatoxin BEnvironmental and molecular mutagenesis · 2025
    Article
  4. Review
  5. Research progress on the role of the NEIL family in cancer.Frontiers in cell and developmental biology · 2025
    Review
  6. Frequencies and spectra of aflatoxin BNAR molecular medicine · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Heather A GalickDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Carolyn G MarsdenDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Scott KatheDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Julie A DragonDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Lindsay VolkPresent address: University of New Mexico, Health Sciences Center, Albuquerque, NM, 87131, USA.
Antonia A NemecDepartment of Biomedical Sciences, Florida State University, Tallahassee, FL, 32306, USA.
Susan S WallaceDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Aishwarya PrakashPresent address: University of South Alabama, Mitchell Cancer Institute, Mobile, AL, 36604, USA.
Sylvie DoubliéDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
Joann B SweasyDepartment of Microbiology and Molecular Genetics, The Markey Center for Molecular Genetics, University of Vermont, Burlington, VT, 05405, USA.
University of Vermont · USFlorida State University · USUniversity of New Mexico · USUSA Mitchell Cancer Institute · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SUBSTRATE SPECIFICITY OF THE BER OXIDATIVE DNA GLYCOSYLASESP01CA098993 · NCI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI LEE, ANDREA J · 2004 to 2021
$25.9M
Repair of Environmentally and Endogenously Induced Mitochondrial-DNA DamageR00ES024417 · NIEHS · UNIVERSITY OF SOUTH ALABAMA · PI PRAKASH, AISHWARYA · 2016 to 2018
$747k
Repair of Environmentally and Endogenously Induced Mitochondrial-DNA DamageK99ES024417 · NIEHS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI PRAKASH, AISHWARYA · 2014 to 2015
$171k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA098993NIEHS NIH HHS K99 ES024417NIEHS NIH HHS R00 ES024417
6 · The paper itself

Abstract

Base excision repair (BER) is a key genome maintenance pathway. The NEIL1 DNA glycosylase recognizes oxidized bases, and likely removes damage in advance of the replication fork. The rs5745906 SNP of the

Indexed as

base excision repairDNA glycosylasegenomic instabilitymutagenesisreplication fork collapse

Identifiers

PMID29156764
PMCPMC5689654
OpenAlexW2750586840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.